iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/39495912/
Mapping the future of oxidative RNA damage in neurodegeneration: Rethinking the status quo with new tools - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 12;121(46):e2317860121.
doi: 10.1073/pnas.2317860121. Epub 2024 Nov 4.

Mapping the future of oxidative RNA damage in neurodegeneration: Rethinking the status quo with new tools

Hailey B Wheeler #  1 , Assael A Madrigal #  1 , Isaac A Chaim  1
Affiliations

Mapping the future of oxidative RNA damage in neurodegeneration: Rethinking the status quo with new tools

Hailey B Wheeler et al. Proc Natl Acad Sci U S A. .

Abstract

Over two decades ago, increased levels of RNA oxidation were reported in postmortem patients with ALS, Alzheimer's, Parkinson's, and other neurodegenerative diseases. Interestingly, not all cell types and transcripts were equally oxidized. Furthermore, it was shown that RNA oxidation is an early phenomenon, altogether indicating that oxidative RNA damage could be a driver, and not a consequence, of disease. Despite all these exciting observations, the field appears to have stagnated since then. We argue that this is a consequence of the shortcomings of technologies to model these diseases, limiting our understanding of which transcripts are being oxidized, which RNA-binding proteins are interacting with these RNAs, what their implications are in RNA processing, and as a result, what their potential role is in disease onset and progression. Here, we discuss the limits of previous technologies and propose ways by which advancements in iPSC-derived disease modeling, proteomics, and sequencing technologies can be combined and leveraged to answer new and decades-old questions.

Keywords: RNA-binding proteins; induced pluripotent stem cells; neurodegeneration; oxidative RNA damage; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

Competing interests statement:The authors declare no competing interest.

Figures

Fig. 1.
Fig. 1.
Proposed link between oxidative RNA lesion-driven defects in RNA processing and other hallmarks of neurodegenerative disease. Donor fibroblasts or PBMCs can be reprogrammed to iPSCs and subsequently differentiated into disease-relevant cell types. iPSC-derived neuronal systems have been shown to closely recapitulate the eight hallmarks of neurodegenerative disease (5) and can be leveraged to elucidate disease-associated mechanisms. The interplay between oxidative RNA damage, impaired RNA processing, and the manifestation of one or more of the shared neurodegenerative phenotypes has yet to be explored. A deeper understanding of converging phenotypes will aid in determining the role of RNA oxidation on dysregulated processes and neurodegenerative disease. Created with BioRender.com.
Fig. 2.
Fig. 2.
Novel detection methodologies for identification of RNA oxidation and their protein interacting partners. Oxidative RNA lesions (in red) can be recognized by RBPs (in dark yellow). To determine the identity of damaged transcripts two approaches can be used. Immunoprecipitation (IP) with anti-lesion antibodies followed by sequencing, or alternatively sequencing (without IP) with a focus on damage signatures introduced during reverse transcription. Lesion-binding RBPs can be identified by novel interactome phase separation methods (OOPS, XRNAX, and LEAP-RBP) via LC–MS. Their RNA targets can be further determined via eCLIP or other recent interactome technologies such as TRIBE, STAMP, and REMORA. The table on the right shows a comparison of previous (1.0) and novel (2.0) methods used for antibody isolation of damaged RNAs, identification of these transcripts, and identification of their interacting RBPs as well as these RBPs’ targets. Created with BioRender.com.
Fig. 3.
Fig. 3.
Knowledge gap in the interactions between neurodegeneration, RNA oxidation, and RBPs. To date, research in the three shown disciplines has focused either on a single discipline or the interactions between two of them. The nature and main takeaways from these interactions are highlighted for each of the three combinations. This work postulates the idea that all three disciplines must be combined, together with novel technological advancements, to explore the potential role that oxidative RNA damage plays in neurodegeneration through RNA processing. Created with BioRender.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rajan K. B., et al. , Population estimate of people with clinical Alzheimer’s disease and mild cognitive impairment in the United States (2020–2060). Alzheimer’s Dement. 17, 1966–1975 (2021). - PMC - PubMed
    1. Yang W., et al. , Current and projected future economic burden of Parkinson’s disease in the U.S. npj Park. Dis. 6, 15 (2020). - PMC - PubMed
    1. Mehta P., et al. , Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017. Amyotroph. Lateral Scler. Front. Degener. 24, 108–116 (2023). - PMC - PubMed
    1. Wyss-Coray T., Ageing, neurodegeneration and brain rejuvenation. Nature 539, 180–186 (2016). - PMC - PubMed
    1. Wilson D. M., et al. , Hallmarks of neurodegenerative diseases. Cell 186, 693–714 (2023). - PubMed

LinkOut - more resources